Panacea Biotec Files Appeal Against Fourth Industrial Tribunal Award; High Court Grants Interim Relief in Earlier Appeals

What Happened ?

key details

Legal Proceedings Update:

• The company received four tribunal awards relating to labour matters.
• According to the tribunal awards:
  • Transfer of 23 workmen was set aside with relief of full back wages from the date of transfer.
  • Reasonable wage revision was awarded for the concerned workmen.
  • Reinstatement of certain workmen (excluding those who had already settled disputes) was ordered with 50% back wages from the date of termination.
• The tribunal awards relate to matters applicable from 2014 onwards.
• Panacea Biotec has now filed appeals against all four awards before the Hon’ble High Court of Punjab and Haryana.
• The High Court has already heard the first three appeals and passed an interim order directing that no coercive action be taken against the company.
• Based on legal advice, the company believes that the tribunal awards are challengeable.

Note:

• The company has specifically stated that, based on its legal assessment, it does not foresee any material adverse impacton its financial position, operations, or other business activities arising from these awards. No penalties, sanctions, or regulatory non-compliances have been identified in the communication.

Risk Analysis

Summary:

• The matter remains under judicial review. While litigation continues, the company has obtained interim relief in three appeals and maintains that no material financial or operational impact is currently expected.

Key Risks:

• Final outcome depends on the High Court’s adjudication.
• Legal proceedings remain ongoing.
• Interim protection has been granted for the first three appeals.
• The company believes the tribunal awards are legally challengeable.
• No material financial impact has been anticipated by management.

Worst Case:

• If the High Court ultimately upholds the tribunal awards, Panacea Biotec may be required to implement the tribunal’s directions relating to reinstatement, wage revisions, and back wages, potentially increasing employee-related liabilities.

Risk Level: Medium

Company Commentary

• Panacea Biotec filed its appeal against the fourth tribunal award on July 16, 2026.
• The High Court has already heard the earlier three appeals and directed that no coercive action be taken against the company.
• Management believes the tribunal awards are legally challengeable based on legal opinion.
• The company does not foresee any material adverse financial, operational, or business impact arising from the awards.